Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016" report to their offering.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. Our latest report Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively.

Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Protein Phosphatase 2A Overview
  3. Therapeutics Development
  4. Pipeline Products for Protein Phosphatase 2A - Overview
  5. Pipeline Products for Protein Phosphatase 2A - Comparative Analysis
  6. Protein Phosphatase 2A - Therapeutics under Development by Companies
  7. Protein Phosphatase 2A - Therapeutics under Investigation by Universities/Institutes
  8. Protein Phosphatase 2A Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Protein Phosphatase 2A - Products under Development by Companies
  13. Protein Phosphatase 2A - Products under Investigation by Universities/Institutes
  14. Protein Phosphatase 2A - Companies Involved in Therapeutics Development
  • Ampio Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cyano Biotech GmbH
  • Lixte Biotechnology Holdings, Inc.
  • Signum Biosciences, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/mhbtdx/protein

View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005869/en/

Business Wire
www.businesswire.com

Last updated on: 12/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.